Depression and heart disease

Psychiatric Annals

Volumn 27, Issue 5, 1997, Pages 347-352

  Shapiro, Peter A ^a   Lidagoster, Lidia ^a,b   Glassman, Alexander H ^a,b  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 6244269228     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19970501-10     Document Type: Article

References (79)

1. Weeke A, Vaeth M. Excess mortality of bipolar and unipolar manic-depressive patients. J Affect Disord. 1986; 11:227-234.
2. Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH. Affective disorders and mortality: a general population study. Arch Gen Psychiatry. 1987; 44:473-480.
3. Bruce ML, Leaf PJ, Rozal GPM, Florio L, Hoff RA. Psychiatric status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. Am J Psychiatry. 1994; 151:716-721.
4. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology. 1993; 4:285-294.
5. Ahern D, Gorkin L, Anderson JL, et al. Biobehavioral variables and mortality or cardiac arrest in the cardiac arrhythmia pilot study (CAPS). Am J Cardiol. 1990; 66:59-62.
6. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation. 1996; 93:1976-1980.
7. Everson SA, Goldberg DE, Kaplan GA, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med. 1996; 58:113-121.
8. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med. 1988; 50:627-633.
9. Ladwig KH, Kieser M, Konig J, Breithardt G, Borggrefe M. Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. Eur Heart J. 1991; 12:959-964.
10. Ladwig KH, Roll G, Breithardt G, Budde T, Borggrefe M. Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet. 1994; 343:20-23.
11. Frasure-Smith N. In-hospital symptoms of psychological stress as predictors of long-term outcome after acute myocardial infarction in men. Am J Cardiol. 1991; 67:121-127.
12. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA. 1993; 270:1819-1825.
13. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis following myocardial infarction. Circulation. 1995; 91:999-1005.
14. Hance M, Carney RM, Freedland KE, Skala J. Depression in patients with coronary heart disease. Gen Hosp Psychiatry. 1996; 18:61-65.
15. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA. 1993; 269:2673-2675.
16. Cooper GL. The safety of fluoxetine - an update. Br J Psychiatry. 1988; 153:877-86.
17. Kuhs H, Rudolf GAE. Cardiovascular effects of paroxetine. Psychopharmacology. 1990; 102:379-382.
18. Roose SP, Glassman AH, Attia E, Woodring S. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Presented at the Annual Meeting of the American Psychiatric Association; Miami, Fla; May 1995.
19. Laghrissi-Thode F, Nelson CJ, Finkel MS, Roose SP. Double-blind study of paroxetine versus nortriptyline in patients with ischemic heart disease. Paper presentation, NCDEU, Boca Raton, Fla; May 1996.
20. Shapiro PA, Glassman AH, Lespérance F, et al. Treatment of major depression after acute myocardial infarction with sertraline: a preliminary study. New Research Program, Annual Meeting, American Psychiatric Association; 1996:249-250. Abstract.
21. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol. 1991; 11:116-120.
22. Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995; 15:23-29.
23. Fava M, Rosenbaum JF, McCarthy M, Pava J, Steingard R, Bless E. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacol Bull. 1991; 27:275-279.
24. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression, part 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry. 1993; 150:1158-1163.
25. Kavoussi RJ, Liu J, Coccaro E. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry. 1994; 55:137-141.
26. Littman AB, Fava M, McKool K, Lamon-Fava S, Pegg E. Buspirone therapy for type A behavior, hostility and perceived stress in cardiac patients. Psychother Psychosom. 1993; 59:107-110.
27. Laghrissi-Thode F, Wagner WR, Pollack BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglogulin plasma levels in patients with ischemic heart disease. Biol Psychiatry. In press.
28. Pollock BG, Laghrissi-Thode F, Wagner WR, Finkel M, Johnson PC. Increased platelet factor 4 and beta-thromboglobulin in depressed patients with ischemic heart disease. Scientific Abstracts of the 34th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, PR; 1995. Abstract 121.
29. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry. 1996; 153:1313-1317.
30. Malzberg B. Mortality among patients with involutional melancholia. Am J Psychiatry. 1937; 93:1231-1238.
31. Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry. 1976; 33:1029-1037.
32. Black DW, Warrack G, Winokur G. Excess mortality among psychiatric patients. The Iowa record-linkage study. JAMA. 1985; 253:58-61.
33. Glassman AH, Stetner F, Walsh T, et al. Heavy smokers, smoking cessation, and clonidine. JAMA. 1988; 259:2863-2866.
34. Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry. 1993; 150:546-553.
35. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989; 149:1785-1789.
36. Carney RM, Rich MW, TeVelde A, Saini J, Clark K, Freedland KE. The relationship between heart rate, heart rate variability and depression in patients with coronary artery disease. J Psychosom Res. 1988; 32:159-164.
37. Roose SP, Glassman AH, Dalack GW. Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry. 1989; 50:12-16.
38. Kleiger RE, Miller JP, Bigger JT, Moss AJ, Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987; 59:256-262.
39. Bigger JT Jr, Kleiger RE, Fleiss JL, et al. Components of heart rate variability during healing of acute myocardial infarction. Am J Cardiol. 1988; 61:208-215.
40. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, part I. N Engl J Med. 1992; 326:242-250.
41. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, part II. N Engl J Med. 1992; 326:310-318.
42. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med. 1993; 329:703-709.
43. McMurray J, Rankin A. Cardiology, I: treatment of myocardial infarction, unstable angina and angina pectoris. BMJ. 1994; 309:1343-1350.
44. Roose SP, Glassman AH, Giardina EGV, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry. 1987; 44:273-275.
45. Roose SP, Glassman AH. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J Clin Psychiatry. 1989; 50:31-18.
46. Roose SP, Glassman AH, Giardina EGV, et al. Nortriptyline in depressed patients with left ventricular impairment. JAMA. 1986; 256:3253-3257.
47. Bigger JT, Giardina EGV, Perel JM, Kantor SJ, Glassman AH. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med. 1977; 296:206-208.
48. Giardina EG, Barnard T, Johnson L, Saroff AL, Bigger JT Jr, Louie M. The antiarrhythmic effect of nortriptyline in cardiac patients with premature ventricular depolarizations. J Am Coll Cardiol. 1986; 7:1363-1369.
49. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989; 321:406-412.
50. CAST II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992; 327:227-233.
51. Echt DS, Liebson PR, Mitchelle LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med. 1991; 324:781-788.
52. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. Circulation. 1991; 84:1977-1983.
53. Lynch JJ, Dicarlo LA, Montgomery DG, Lucchesi BR. Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. Pharmacology. 1987; 35:181-193.
54. Ellison JM, Milofsky JE, Ely E. Fluoxetine induced bradycardia and syncope in two patients. J Clin Psychiatry. 1990; 51:385-386.
55. Feder R. Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry. 1991; 52:138-139.
56. Berk M, Jacobson BF, Hurly E. Fluoxetine and hemostatic function: a pilot study. J Clin Psychiatry. 1995; 56:14-16.
57. Askinazi C. SSRI treatment of depression with comorbid cardiac disease. Am J Psychiatry. 1996; 153:135-136.
58. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994; 151:1735-1739.
59. Barefoot JC, Dahlstrom WG, Williams RB. Hostility, CHD incidence, and total mortality: a 25-year follow-up study of 255 physicians. Psychosom Med. 1983; 45:59-63.
60. Shekelle RB, Gale M, Ostfeld AM, Paul O. Hostility, risk of coronary heart disease, and mortality. Psychosom Med. 1983; 45:109-114.
61. Sloan RP, Shapiro PA, Bigger JT, Bagiella E, Steinman RC, Gorman JM. Cardiac autonomic control and hostility in healthy subjects. Am J Cardiol. 1994; 74:298-300.
62. Williams RB, Barefoot JC, Lee KL, Kong Y, Blumenthal J, Whalen R. Type A behavior, hostility, and coronary atherosclerosis. Psychosom Med. 1980; 42:539-549.
63. Williams RB. Patterns of reactivity and stress. In: Matthews KA, Weiss SM, Detre T, et al, eds. Handbook of Stress, Reactivity, and Cardiovascular Disease. New York, NY: Wiley; 1986:109-125.
64. Clarkson TB. Personality, gender, and coronary artery atherosclerosis of monkeys. Arteriosclerosis. 1987; 7:1-8.
65. Kaplan JR, Adams MR, Clarkson TB, Koritnik D. Psychosocial influences on female 'protection' among cynomolgus macaques. Atherosclerosis. 1984; 53:283-295.
66. Kaplan JR, Manuck SB, Clarkson TB. Social status, environment, and atherosclerosis in cynomolgus monkeys. Atherosclerosis. 1982; 2:359-366.
67. Kaplan JR, Manuck SB, Clarkson TB, Lusso FM, Taub DM, Miller EW. Social stress and atherosclerosis in normocholesterolemic monkeys. Science. 1983; 220:733-735.
68. Manuck SB, Olsson G, Hjemdahl P, Rehnqvist N. Does cardiovascular reactivity to mental stress have prognostic value in postinfarction patients? A pilot study. Psychosom Med. 1992; 54:102-108.
69. Krantz DS, Helmers KF, Bairey CN, Nebel LE, Hedges SM, Rozanski A. Cardiovascular reactivity and mental stress-induced myocardial ischemia in patients with coronary artery disease. Psychosom Med. 1991; 53:1-12.
70. Blumenthal JA, Jiang W, Waugh RA, et al. Mental stress-induced ischemia in the laboratory and ambulatory ischemia during daily life. Association and hemodynamic features. Circulation. 1995; 92:2102-2108.
71. Jiang W, Babyak M, Krantz DS, et al. Mental stress - induced myocardial ischemia and cardiac events. JAMA. 1996; 275:1651-1656.
72. Asberg M. Psychobiology of suicide, impulsivity and related phenomena. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:655-668.
73. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal fluid metabolites. Psychiatry Res. 1979; 1:131-139.
74. Brown GL, Ebert MH, Goyer PF, et al. Aggression, suicide and serotonin. Relationships to CSF metabolites. Am J Psychiatry. 1982; 139:741-745.
75. Roy A, Adinoff B, Linnoila M. Acting out hostility in normal volunteers: negative correlation with levels of 5HIAA in cerebrospinal fluid. Psychiatry Res. 1988; 24:187-194.
76. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive and aggressive behavior. Arch Gen Psychiatry. 1989; 46:587-599.
77. Coccaro EF, Gabriel S, Siever LJ. Buspirone challenge: preliminary evidence for a role of central 5-HT1a receptor function in impulsive aggressive behavior in humans. Psychopharmacol Bull. 1990; 26:393-406.
78. Ratey J, Sovner R, Parks A. Buspirone treatment of aggression and anxiety in mentally retarded patients. A multiple-baseline, placebo lead-in study. J Clin Psychiatry. 1991; 52:159-162.
79. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996; 153:311-320.